<DOC>
	<DOCNO>NCT00003316</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness gemcitabine treat patient recurrent refractory cancer uterus .</brief_summary>
	<brief_title>Gemcitabine Treating Patients With Recurrent Refractory Cancer Uterus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity gemcitabine patient recurrent persistent leiomyosarcoma uterus fail high priority treatment protocol . II . Determine toxicity gemcitabine patient . OUTLINE : Patients receive gemcitabine IV 30 minute weekly 3 week . Courses repeat every 4 week absence unacceptable toxicity disease progression . Patients partial response , complete response , stable disease receive least 3 course therapy . Patients follow every 3 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 40 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent persistent uterine leiomyosarcoma refractory curative therapy standard treatment Failed local therapeutic measure consider incurable Measurable disease Not eligible high priority GOG protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 1.5 mg/dL Other : No significant infection At least 5 year since invasive malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy Chemotherapy : At least 3 week since prior chemotherapy recover No prior gemcitabine No 1 prior chemotherapy regimen ( single agent combination therapy ) Endocrine therapy : At least 3 week since prior endocrine therapy Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : At least 3 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
</DOC>